1094 related articles for article (PubMed ID: 15122171)
21. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?
Falcó V; Almirante B; Jordano Q; Calonge L; del Valle O; Pigrau C; Planes AM; Gavaldà J; Pahissa A
J Antimicrob Chemother; 2004 Aug; 54(2):481-8. PubMed ID: 15215226
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
Ishida T; Maniwa K; Kagioka H; Hirabayashi M; Onaru K; Tomioka H; Hayashi M; Tomii K; Gohma I; Ito Y; Hirai T; Ito I; Mishima M
Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022
[TBL] [Abstract][Full Text] [Related]
23. Resistance among Streptococcus pneumoniae: Implications for drug selection.
Appelbaum PC
Clin Infect Dis; 2002 Jun; 34(12):1613-20. PubMed ID: 12032897
[TBL] [Abstract][Full Text] [Related]
24. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
[TBL] [Abstract][Full Text] [Related]
25. [Sensitivity of Streptococcus pneumoniae to antimicrobial drugs].
Mihajlović-Ukropina M; Milutinović M
Med Pregl; 1998; 51(3-4):169-73. PubMed ID: 9611963
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
27. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
29. Severe pneumococcal pneumonia: new strategies for management.
Chiou CC; Yu VL
Curr Opin Crit Care; 2006 Oct; 12(5):470-6. PubMed ID: 16943728
[TBL] [Abstract][Full Text] [Related]
30. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome.
Bonnard P; Lescure FX; Douadi Y; Schmit JL; Jounieaux V; Laurans G; Eb F; Ducroix JP
J Infect; 2005 Jul; 51(1):69-76. PubMed ID: 15979494
[TBL] [Abstract][Full Text] [Related]
31. [Pneumococcal antibiotic resistance].
Moreillon P; Wenger A; Caldelari I
Rev Med Suisse Romande; 2000 Aug; 120(8):651-9. PubMed ID: 11028185
[TBL] [Abstract][Full Text] [Related]
32. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
[TBL] [Abstract][Full Text] [Related]
33. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
34. [Antibiotic resistance in pneumococci].
Moreillon P; Wenger A
Schweiz Med Wochenschr; 1996 Feb; 126(7):255-63. PubMed ID: 8720323
[TBL] [Abstract][Full Text] [Related]
35. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
Low DE
Clin Infect Dis; 2004 May; 38 Suppl 4():S357-62. PubMed ID: 15127370
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
37. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities.
Klugman KP; Low DE; Metlay J; Pechere JC; Weiss K
Int J Antimicrob Agents; 2004 Nov; 24(5):411-22. PubMed ID: 15519470
[TBL] [Abstract][Full Text] [Related]
38. Drug treatment of pneumococcal pneumonia in the elderly.
Neralla S; Meyer KC
Drugs Aging; 2004; 21(13):851-64. PubMed ID: 15493950
[TBL] [Abstract][Full Text] [Related]
39. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative.
Nuermberger E; Bishai WR
Clin Infect Dis; 2004 Jan; 38(1):99-103. PubMed ID: 14679455
[TBL] [Abstract][Full Text] [Related]
40. [Current use of penicillin in community-acquired pneumococcal pneumonias].
Gaztelurrutia L; Zalacaín R; Rubio G; Hernández JL; Urra E; Hernández M; Garea C; Barrón J
Enferm Infecc Microbiol Clin; 1994 Jan; 12(1):17-20. PubMed ID: 8155749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
